Characteristic | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age, years | ||||
≥ 75 vs < 75 | 0.62 (0.39–0.98) | 0.04 | 0.55 (0.35–0.87) | 0.01 |
Gender | ||||
Male vs female | 1.18 (0.82–1.71) | 0.36 | – | |
Metastatic site, yes vs no | ||||
Bone | 1.35 (0.99–1.84) | 0.06 | – | |
Liver | 1.05 (0.76–1.46) | 0.75 | – | |
CNS | 1.39 (0.84–2.31) | 0.20 | – | |
Number of prior therapies | ||||
> 1 vs 1 | 1.80 (1.15–2.87) | 0.01 | – | |
First line | ||||
Sunitinib vs pazopanib | 1.24 (0.84–1.84) | 0.28 | ||
Prior everolimus | ||||
Yes vs no | 1.30 (0.95–1.76) | 0.10 | ||
Drug-related toxicity (drAEs) | ||||
Yes vs no | 0.64 (0.46–0.91) | 0.01 | – | |
Ir toxicity (irAEs) | ||||
Yes vs no | 0.48 (0.30–0.78) | 0.003 | 0.57 (0.35–0.93) | 0.02 |
Number of Nivolumab doses | ||||
> 4 vs ≤4 | 0.11 (0.08–0.15) | < 0.0001 | 0.11 (0.08–0.15) | < 0.0001 |